Abstract
Cancer incidence increases with advanced age. The Cancer and Aging Research Group, in partnership with the National Institute on Aging and NCI, have summarized the gaps in knowledge in geriatric oncology and made recommendations to close these gaps. One recommendation was that the comprehensive geriatric assessment (CGA) should be incorporated within geriatric oncology research. Information from the CGA can be used to stratify patients into risk categories to better predict their tolerance of cancer treatment, and to follow functional consequences from treatment. Other recommendations were to design trials for older adults with study end points that address the needs of the older and/or vulnerable adult with cancer and to build a better infrastructure to accommodate the needs of older adults to improve their representation in trials. We use a case-based approach to highlight gaps in knowledge regarding the care of older adults with cancer, discuss our current state of knowledge of best practice patterns, and identify opportunities for research in geriatric oncology. More evidence regarding the treatment of older patients with cancer is urgently needed.
Key Points
-
The available evidence suggests that functional limitations, comorbidity, cognitive decline, and/or limited social support correlate with toxicity to therapy and cancer outcomes in patients aged 65 and over
-
Information from the comprehensive geriatric assessment can be used to stratify patients into risk categories to better predict their tolerance to treatment and follow functional consequences from treatment
-
Although fit, older adults do as well as their younger counterparts when receiving treatment within clinical trials, older adults are at increased risk for treatment-related toxic effects
-
The proportion of older adults in trials should include those with underlying health status characteristics that better reflect the age and health status of patients seen in the community
-
The focus for treatment within oncology clinical research to be 'more aggressive' continues to accentuate the current under-representation of older adults
-
When caring for older cancer patients in oncology offices, the necessary additional time should be provided to perform assessments and to monitor and manage toxicities
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jemal, A., Siegel, R., Xu, J. & Ward, E. Cancer statistics, 2010. CA Cancer J. Clin. 60, 277–300 (2010).
Smith, B. D., Smith, G. L., Hurria, A., Hortobagyi, G. N. & Buchholz, T. A. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J. Clin. Oncol. 27, 2758–2765 (2009).
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. Jr & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061–2067 (1999).
Crome, P. & Flanagan, R. J. Pharmacokinetic studies in elderly people. Are they necessary? Clin. Pharmacokinet. 26, 243–247 (1994).
Zafar, S. F. et al. Participation and survival of geriatric patients in phase I clinical trials: The Karmanos Cancer Institute (KCI) experience. J. Geriatr. Oncol. 2, 18–24 (2011).
Lichtman, S. M. Clinical trial design in older adults with cancer—the need for new paradigms. J. Geriatr. Oncol. http://dx.doi.org/10.1016/j.jgo.2012.03.002 (2012).
Hurria, A. & Lichtman, S. M. Pharmacokinetics of chemotherapy in the older patient. Cancer Control 14, 32–43 (2007).
Owusu, C., Koroukian, S. M., Schluchter, M., Bakaki, P. & Berger, N. Screening older cancer patients for a comprehensive geriatric assessment: a comparison of three instruments. J. Geriatr. Oncol. 2, 121–129 (2011).
Hurria, A., Cohen, H. J. & Extermann, M. Geriatric oncology research in the cooperative groups: a report of a SIOG special meeting. J. Geriatr. Oncol. 1, 40–44 (2010).
Dale, W. et al. Biological, clinical, and psychosocial correlates at the interface of cancer and aging research. J. Natl Cancer Inst. 104, 581–589 (2012).
Hurria, A. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 29, 3457–3465 (2011).
Extermann, M. et al. Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score. Cancer 118, 3377–3386 (2011).
Dale, W. “Staging the aging” when considering androgen deprivation therapy for older men with prostate cancer. J. Clin. Oncol. 27, 3420–3422 (2009).
Rodin, M. B. & Mohile, S. G. A practical approach to geriatric assessment in oncology. J. Clin. Oncol. 25, 1936–1944 (2007).
Hurria, A. et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer 104, 1998–2005 (2005).
Mohile, S. G. et al. A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109, 802–810 (2007).
Extermann, M. & Hurria, A. Comprehensive geriatric assessment for older patients with cancer. J. Clin. Oncol. 25, 1824–1831 (2007).
Hurria, A. et al. Identifying vulnerable older adults with cancer: integrating geriatric assessment into oncology practice. J. Am. Geriatr. Soc. 55, 1604–1608 (2007).
Repetto, L. et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J. Clin. Oncol. 20, 494–502 (2002).
Hurria, A. et al. Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. J. Clin. Oncol. 26, 3125–3127 (2008).
Hurria, A. Clinical trials in older adults with cancer: past and future. Oncology (Williston Park) 21, 351–358 (2007).
Yonemori, K. et al. Do investigators show selection biases when enrolling patients in phase I oncology registration trials? J. Geriatr. Oncol. 2, 25–30 (2011).
Pal, S. K., Katheria, V. & Hurria, A. Evaluating the older patient with cancer: understanding frailty and the geriatric assessment. CA Cancer J. Clin. 60, 120–132 (2010).
Mohile, S. G. et al. Association of a cancer diagnosis with vulnerability and frailty in older Medicare beneficiaries. J. Natl Cancer Inst. 101, 1206–1215 (2009).
François, E. et al. Use of bevacizumab in elderly patients with metastatic colorectal cancer: Review. J. Geriatr. Oncol. 2, 65–71 (2011).
Hurria, A. et al. Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J. Clin. Oncol. 29, 1290–1296 (2011).
Fried, T. R., Bradley, E. H., Towle, V. R. & Allore, H. Understanding the treatment preferences of seriously ill patients. N. Engl. J. Med. 346, 1061–1066 (2002).
Hurria, A., Mohile, S. G. & Dale, W. Research priorities in geriatric oncology: addressing the needs of an aging population. J. Natl Compr. Canc. Netw. 10, 286–288 (2012).
Seymour, M. T. et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 377, 1749–1759 (2011).
Soubeyran, P. et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J. Clin. Oncol. 30, 1829–1834 (2012).
Kanesvaran, R., Li, H., Koo, K. N. & Poon, D. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J. Clin. Oncol. 29, 3620–3627 (2011).
Pawelec, G., Derhovanessian, E. & Larbi, A. Immunosenescence and cancer. J. Geriatr. Oncol. 1, 20–26 (2010).
Driver, J. A. Understanding the link between cancer and neurodegeneration. J. Geriatr. Oncol. 3, 58–67 (2012).
Vandenberk, B., Brouwers, B., Hatse, S. & Wildiers, H. p16INK4a: a central player in cellular senescence and a promising aging biomarker in elderly cancer patients. J. Geriatr. Oncol. 2, 259–269 (2011).
Skirvin, J. A. & Lichtman, S. M. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 19, 25–42 (2002).
VanderWalde, A. M. & Hurria, A. Second malignancies among elderly survivors of cancer. Oncologist 16, 1572–1581 (2011).
Dotan, E., Browner, I., Hurria, A. & Denlinger, C. Challenges in the management of older patients with colon cancer. J. Natl Compr. Canc. Netw. 10, 213–225 (2012).
Mohile, S. G. & Wildiers, H. Rethinking observational cohort studies in geriatric oncology. J. Geriatr. Oncol. 3, 291–293 (2012).
Walter, L. C. & Covinsky, K. E. Cancer screening in elderly patients: a framework for individualized decision making. JAMA 285, 2750–2756 (2001).
Given, B. & Given, C. W. Cancer treatment in older adults: implications for psychosocial research. J. Am. Geriatr. Soc. 57 (Suppl. 2), S283–S285 (2009).
Reuben, D. B. in Geriatric Medicine: An Evidence-based Approach 4th edn (eds Cassel, C. K., Leipzig, R., Cohen, H. J, Larson, E. B. & Meier, D. E.) 195–204 (Springer, New York, 2003).
Sajid, S., Mohile, S. G., Szmulewitz, R., Posadas, E. & Dale, W. Individualized decision-making for older men with prostate cancer: balancing cancer control with treatment consequences across the clinical spectrum. Semin. Oncol. 38, 309–325 (2011).
Author information
Authors and Affiliations
Contributions
S. Mohile and A. Hurria researched the data for the article. All authors contributed to discussions of the content, wrote and edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
A. Hurria has received research support from the following companies: Celgene and GlaxoSmithKline. A. Hurria has also acted as a consultant for the following companies: Genentech, GTx and Seattle Genetics. The other authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Mohile, S., Dale, W. & Hurria, A. Geriatric oncology research to improve clinical care. Nat Rev Clin Oncol 9, 571–578 (2012). https://doi.org/10.1038/nrclinonc.2012.125
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2012.125
This article is cited by
-
Selected Domains within a Comprehensive Geriatric Assessment in Older Patients with Non-Hodgkin Lymphoma are Highly Associated with Frailty
Clinical Hematology International (2022)
-
Psychological Aspects to Consider in Breast Cancer Diagnosis and Treatment
Current Oncology Reports (2021)
-
Attitudes of older adults with serious competing health risks toward their implantable cardioverter-defibrillators: a pilot study
BMC Geriatrics (2015)
-
Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study
Cancer Chemotherapy and Pharmacology (2015)
-
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report
Journal of Gastrointestinal Cancer (2015)